Similar articles

• Systemic chemotherapy in the treatment of malignant melanoma.

  Lens MB, Eisen TG. Lens MB, et al. Expert Opin Pharmacother. 2003 Dec;4(12):2205-11. doi: 10.1517/14656566.4.12.2205. Expert Opin Pharmacother. 2003. PMID: 14640919 Review.
• Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.

  Vuoristo M, Gröhn P, Kumpulainen E, Korpela M. Vuoristo M, et al. Eur J Cancer. 1994;30A(3):420. doi: 10.1016/0959-8049(94)90278-x. Eur J Cancer. 1994. PMID: 7515632 Clinical Trial. No abstract available.
• Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.

  Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Melanoma Res. 2005 Aug;15(4):291-6. doi: 10.1097/00008390-200508000-00010. Melanoma Res. 2005. PMID: 16034308 Clinical Trial.
• Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

  Punt CJ, van Herpen CM, Jansen RL, Vreugdenhil G, Muller EW, de Mulder PH. Punt CJ, et al. Br J Cancer. 1997;76(2):266-9. doi: 10.1038/bjc.1997.374. Br J Cancer. 1997. PMID: 9231931 Free PMC article. Clinical Trial.
• [Chemotherapy of malignant melanoma].

  Avril MF. Avril MF. Ann Dermatol Venereol. 1988;115(9):959-68. Ann Dermatol Venereol. 1988. PMID: 2464963 Review. French. No abstract available.